Success Metrics

Active Trials

3(75%)

Phase Distribution

Ph phase_1

75%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 3Large-scale testing

1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Detailed Status

Recruiting3

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 13 (75.0%)

Phase 31 (25.0%)

Trials by Status

not_yet_recruiting125%

recruiting375%

Recent Activity

3 active trials

Showing 4 of 4

recruitingphase_3

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

NCT07099898

recruitingphase_1

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

NCT07602777

not_yet_recruitingphase_1

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

NCT07602855

recruitingphase_1

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142

Clinical Trials (4)

Showing 4 of 4 trials

NCT07099898Phase 3

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

Recruiting

NCT07602777Phase 1

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

Recruiting

NCT07602855Phase 1

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

Not Yet Recruiting

NCT06551142Phase 1

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

Recruiting

All 4 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 4